Newsfeeds - Spark Newswire

3 minute read

Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels

Today, 4:24 AM

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in

LEXX

2 minute read

$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 4:24 AM

The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

GLT

2 minute read

Lexaria’s Human Oral Nicotine Study Begins Dosing

By Benzinga Newsdesk

Today, 4:24 AM

Lexaria's DehydraTECH-nicotine pouch performance to be compared to existing leading brands ON! and Zyn KELOWNA, BC / ACCESSWIRE / December 20, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the

LEXX

4 minute read

Lexaria Bioscience Turns Focus To Dementia And Diabetes With New Studies

By Benzinga Newsdesk

Today, 4:24 AM

PCG Digital -- Lexaria Bioscience (NASDAQ:LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world's biggest public health

LEXX

4 minute read

Lexaria’s Human Clinical HYPER-H21-4 Study

By Benzinga Newsdesk

Today, 4:24 AM

HYPER-H21-4 using DehydraTECH-CBD evidenced: Exceptional safety and tolerability Statistically significant lowering of 24-hour ambulatory blood pressure ("BP") BP lowered for the entire 5-week study

LEXX

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 4:24 AM

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…

BBIO

1 minute read

Lexaria Gets FDA’s Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate

By Ragothaman Srinivasan

Today, 4:24 AM

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting regarding DehydraTECH-CBD for the treatment of hypertension.

LEXX

4 minute read

Recap of Wednesday’s Biotech Catalysts – End of The Day Summary

By Ragothaman Srinivasan

Today, 4:24 AM

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…

ABBV

3 minute read

Lexaria’s DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events

By Vuk Zdinjak

Today, 4:24 AM

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

LEXX

2 minute read

Global
News

Lexaria’s Licensee Premier Wellness Science Co., Ltd. Launches New Brand In Preparation To Deploy DehydraTECH CBD Products In Japan

By Benzinga Newsdesk

Today, 4:24 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its exclusive* Japanese Licensee,

LEXX